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ABSTRACT   
 Hyperlipidemia is elevated level of lipids or lipoproteins in our body. Cholesterol is a major 
lipid particle circulating in our body. Cholesterol synthesis takes place in liver and this 
biosynthesis pathway is called Mevalonate pathway. Cholesterol is the end product of this 
Mevalonate pathway. Several enzymes play a role in the Cholesterol biosynthesis. Enzymes 
like HMGCoA synthase, HMGCoA reductase, Farnesyl PP synthase, Lanosterol synthase, 
Squalene synthase. This cholesterol is mainly responsible for several health effects especially 
Coronary heart diseases, atherosclerosis etc. So now in order to prevent the cholesterol 
synthesis in our body, we need to find potent inhibitors against the above enzymes and there 
after modify them as drugs. In this study, two enzymes HMGCoA reductase and Lanosterol 
synthase were targeted. For our docking study, we used Arguslab, Mgl tools, Autodock vina 
softwares for obtaining binding energies of protein and ligands. We search for already available 
drugs acting against HMGCoA reductase called Statins. We obtained binding energy results 
with NADH, PRAVASTATIN, LOVASTATIN, CERIVASTATIN, SIMVASTATIN, 
FLUVASTATIN, BEZAFIBRATE and note them as POSITIVE CONTROL 1. Then we dock 
HMGCoA reductase with natural molecules and compare them with positive control 1. In the 
next step, we targeted Lanosterol Synthase with available Quinuclidine inhibitors and results 
obtained was noted as POSITIVE CONTROL 2. Now we cross docked Lanosterol synthase 
with previous natural ligands and compared them with Positive control 2. We later found the 
toxicity and druglikeness of all inhibitors used against both the targets. We found two natural 
molecules APIGENIN and NARINGENIN which showed best binding energy results against 
both the targets. Both Apigenin and Naringenin act as suitable inhibitors against HMGCoA 
reductase and Lanosterol synthase inhibiting at two places along the Mevalonate pathway. 
 
KEY WORDS -  
Hyperlipidemia, cholesterol, HMGCoA reductase, Lanosterol synthase, Statins, 
Apigenin, Naringenin 
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1. INTRODUCTION 
Hyperlipidemia or hypercholesterolemia is an abnormal elevation in the level of lipids or 
lipoproteins in our body. Usually level of lipid rises in the blood. Cholesterol is a lipid 
circulating in our blood. Hypercholesterolomia is a specific case of hyperlipidemia where the 
level of cholesterol increases in the blood. Cholesterol is insoluble in water, it is transported in 
the blood plasma with other lipoproteins.Different classifications of lipoproteins include-Very 
Low Density Lipoprotein(VLDL), Low Density Lipoprotein(LDL), High Density 
Lipoproteins(HDL), Intermediate Density Lipoprotein(IDL). Cholesterol is carried by all 
lipoproteins and usually LDL cholesterol is risky known as Bad Cholesterol. It is known to 
cause Coronary heart disease and atherosclerosis. Most cholesterol in our body is produced due 
to internal synthesis in liver. Other sources include dietary sources, genetic influence. 
Cholesterol has many functions in our body like absorption of fats and hormones like 
testosterone, estrogen, progesterone, cortisol etc. Cholesterol helps for production of Vitamin-
D in the presence of sun light. It is essential for providing structural support to cell membranes, 
serves as antioxidant, and helps in conduction of nerve impulses. 
 
An important pathway takes place in liver called Cholesterol synthesis pathway or Mevalonate 
pathway. HMGCR or HMG-CoA reductase is an important enzyme which controls the rate of 
the pathway. Cholesterol will be the final product of this pathway. Other   important enzymes 
involved in this pathway include Lanosterol synthase, Farnesyl diphosphate synthase, HMG-
CoA synthase. Detailed analysis of pathway includes one molecule of Acetyl-CoA combining 
with one molecule of Acetoacetyl-CoA forming HMG-CoA . HMG-CoA is reduced to 
Mevalonic acid/Mevalonate by an enzyme called HMG-CoA reductase. 
Mevalonate/Mevalonic acid is now converted to Isopentyl pyrophosphate. Isopentyl 
pyrophosphate gets converted to Farnesyl pyrophosphate in the presence of Farnesyl-PP-
Synthase. Two molecules of Farnesyl pyrophosphate condense to forming Squalene by action 
involving Squalene synthase. Squalene cyclists forming Lanosterol. Lanosterol gets converted 
to Cholesterol finally in the presence of Lanosterol synthase. 
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 Now we choose to important enzymes as targets for our study. They are HMG-CoA reductase 
and Lanosterol synthase. HMG-CoA reductase is a major target for cholesterol lowering drugs. 
We study about a class of already available inhibitors to HMG-CoA reductase in the market 
called as Statins. Statins are found to prevent cardiovascular diseases and other cholesterol 
diseases. By inhibiting HMG-CoA reductase, Statins block the synthesis pathway in liver. Now 
by reduction of cholesterol production in the liver, level of cholesterol in blood falls. Examples 
of Statins are Fluvastatin, Lovastatin, Simvastatin, Mevastatin, Pravastatin, Atorvastatin, 
Rosuvastatin, Cerivastatin. Now we perform docking study retrieving PDB ID of our target, 
predicting the active sites of our target, perform docking by using docking tools. We choose 
protein model with PDB ID : 1DQ9 for HMG-CoA reductase. Predict active site catalytic 
portions using CASTP and obtain GLU559, LYS691, ASP767 and HIS866 as aminoacid 
catalytic portions. We perform docking using Autodock Vina, ArgusLab and obtain binding 
energies with different inhibitors both predicted and already available inhibitors. Potential 
molecules that are reported from this study can be assayed for development into new drugs. 
Similarly we choose PDB ID: 1W6J for Lanosterol synthase, predict the active sites of 
Lanosterol found to be HIS232, ASP455 and perform similar docking study as done in the case 
of HMG-CoA reductase. We identify a class of Quinuclidine inhibitors for Lanosterol synthase. 
Other classes are identified as Azole inhibitors and Novel-4-piperidino pyridine inhibitors. We 
predict the toxicity and druglikeliness of all our inhibitors. 
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2. REVIEW OF LITERATURE 
2.1 HYPERLIPIDEMIA/LIPIDS/LIPOPROTEIN/CHOLESTEROL                                                            
Hyperlipidemia involves high level of lipids or lipoproteins in our blood. It is a form of 
dyslipidemia. Cholesterol circulating in our blood when rises to abnormal level forms 
Hypercholesterolemia [3]. Lipoprotein is a biochemical assembly of both lipid and protein. 
They allow mobilization of fats and water through cell membranes. Lipids include fats, sterols, 
waxes, glycerides, vitamins etc. Hyperlipidemia is bound to cause coronary heart diseases, 
ischemic heart diseases, atherosclerotic heart diseases. Arteries get blocked due to cholesterol 
deposition, leading to narrowing, blocking reducing blood flow in heart. Cholesterol is a lipid 
particle which circulates in our body. Cholesterol acts as a crucial substance and performs some 
vital functions in our body.  
Lipoproteins are classified into -  
1. Very Low Density Lipoproteins (VLDL) 
2. Low Density Lipoprotein (LDL) 
3. Intermediate Density Lipoprotein (IDL) 
4. High Density Lipoprotein (HDL) 
5. Triglycerides 
2.2 CAUSES OF HYPERLIPIDEMIA 
There are many factors for the elevation of lipid level in our body. It is found that food habits, 
daily living conditions, stress, obesity etc may induce the level of lipid in our body. Some of 
the causes are found to be -  
 Obesity  
 Stress 
 Food habits ( Eating food containing saturated fats, trans fats etc ) 
 Age factor 
 Smoking 
 Genetic factor ( Heredity ) 
 Metabolic syndrome 
 Hypothyroidism 
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 Main cause of lipid elevation is internal biosynthesis of cholesterol which takes place 
in the liver. 
Internal biosynthesis mechanism is the main cause for high lipid level elevation in our body. 
Many factors exacerbate the rate of production of lipids in our body.  
2.3 DETAILED DESCRIPTION OF BIOSYNTHESIS PATHWAY OF 
CHOLESTEROL IN LIVER  
One molecule of Acetyl COA and one molecule of Acetoacetyl COA combine to form 
HMGCoA. HMGCoA is reduced to Mevalonate by an enzyme HMGCoA reductase. 
Mevalonate is now converted to Isopentylpyrophosphate. Isopentylpyrophosphate is converted 
to Farnesylpyrophosphate. Two molecules of Farnesylpyrophosphate condense to form 
Squalene by action of Squalene by Squalenesynthase. Squalenesynthase cyclizes to form 
Lanosterol in the presence of Lanosterolsynthase. Finally Lanosterol gets converted 
Cholesterol.  
 
Figure 1: Shows mevalonate pathway i.e biosynthesis of Cholesterol in Liver ( Reference: AACR 
publications ) 
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2.4 ROLE OF DIFFERENT ENZYMES IN CHOLESTEROL SYNTHESIS PATHWAY 
1. Enzyme HMGCoA synthase binds to substrate Acetoacetyl CoA giving rise to HMGCoA.  
2. Enzyme HMGCoA reductase binds to substrate HMGCoA giving rise to Mevalonic acid. 
3. Enzyme Mevalonate kinase binds to substrate Mevalonic acid giving rise to Mevalonate-
5-phosphate 
4. Enzyme Phosphomevalonate kinase binds to Mevalonate-5-phosphate giving rise to 
Mevalonate-5-pyrophosphate. 
5. Enzyme Mevalonate-5-pyrophosphate decarboxylase binds to Mevalonate-5-
pyrophosphate giving rise to Isopentyl-5-pyrophosphate. 
6. Enzyme Farnesyl PP synthase converts Isopentyl-5-pyrophosphate to Farnesyl PP. 
7. Later Lanosterol synthase converts Squalene to Lanosterol. 
8. In the last step, Squalene lanosterol gets converted to Cholesterol 
2.5 AVAILABLE DRUGS AGAINST HMGCoA REDUCTASE: THE STATINS [10] 
There are a class of already available drugs called Statins used to lower cholesterol levels in 
our body by inhibiting HMGCoA reductase. Statins [14] are been found to prevent 
cardiovascular diseases and other diseases caused by elevated level of Cholesterol. By 
inhibiting HMGCoA reductase, statins block the pathway for synthesis of cholesterol in the 
liver. By reducing or checking Cholesterol production in the liver, cholesterol levels in the 
blood fall. Statins act by competitively inhibiting HMGCoA reductase [12]. Statins are almost 
similar to HMGCoA on molecular level and thus take place of HMGCoA. This reduces the rate 
by which mevalonate is produced in liver thereby blocking the pathway. Cholesterol synthesis 
occurs mostly in the nights, so statins usually having short half-lives are usually taken at night 
to maximize their effect. Statins are HMGCoA Reductase inhibitors [17] with an inhibition 
constant value in the range of nanomolar level and effectively lower amount of cholesterol 
present in blood serum. Statins are extensively prescribed and used for the treatment of 
hypercholesterolemia/hyperlipidemia. Statins usually occupy an amino acid residue portion of 
the binding site of HMGCoA, thus blocking the access of substrate HMGCoA to the active site 
catalytic portion of enzyme HMGCoA reductase. Near the carboxyl terminus of HMGCoA 
reductase, we find many catalytically pertinent amino acid residues which get disordered in the 
complex formation of HMGCoA reductase-statin complexes. Flexibility of these residues plays 
a major role in complex formation as they would hinder the statin binding sterically.  
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2.6 AVAILABLE INHIBITORS AGAINST LANOSTEROL SYNTHASE  
Lanosterol synthase is an Oxidsqualene cyclase enzyme which converts 2,3 Oxidosqualene to 
a protosterol cation which finally gets converted into Lanosterol synthase [7]. Lanosterol is a 
four ringed intermediate in the formation of cholesterol. Today, interest has grown to use 
inhibitors of Lanosterol synthase as drugs to lower the level of Cholesterol in the blood and 
also to treat wide variety of diseases caused by increased level of Cholesterol like 
Atherosclerosis, Coronary heart diseases etc. More interest is grown when Statins showed 
many side effects.  
A class of Quinuclidine inhibitors [6], Piperidino-pyridine inhibitors, AZOLE inhibitors are 
found to inhibit the enzyme substrate binding and prevent the pathway from proceeding further. 
 
Figure 2: Shows chemical structure of Cholesterol with molecular formula C27H46O 
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3. OBJECTIVES 
 Selection of required targets in the pathway. 
 Virtual screening of target with already available inhibitors. 
 Prediction of active sites of our target. 
 Identifying a range of binding energies obtained by docking with already available 
inhibitors. 
 Screening of selected natural compounds based on their binding energies near the active 
site of the enzyme. 
 Determining binding energies obtained by docking with natural compounds. 
 Screening of selected compounds based on binding energy greater than or in the range 
of binding energies obtained with available inhibitors. 
 Analysing the docking result for identification of potential inhibitor molecule. 
 Prediction of toxicity of all inhibitors used against our targets. 
 Calculating Druglikeness properties like LogP, Molar refractivity of all inhibitors. 
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4. PLAN OF WORK 
 PART I 
Selection of our Target HMGCoA reductase by studying the Mevalonate pathway 
 
Retrieval of HMGCoA reductase structure from PDB (PDB id. 1DQ9) 
 
Prediction of active sites of HMGCoA reductase using CASTP 
 
Identification of potential binding pockets in the target enzyme 
 
Identification of already available drugs which are used to inhibit HMGCoA reductase 
 
Preparing the HMGCoA reductase molecule for docking with already available drugs using 
Autodock VINA 
 
Selection of the best binding energy results as Positive control for further study 
 
Literature review of natural molecules which can act as inhibitors for HMGCoA reductase 
 
Docking of small molecule retrieved from natural product with HMGCoA reductase 
 
Screening of docked molecule based on highest binding energy 
 
Docking of target enzyme-substrate to determine the binding energy of interaction 
 
Screening of selected compounds based on binding energy greater than that of binding 
energies obtained with already available drugs. 
 
Analysis of docking result for identification of potential inhibitor molecule. 
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 PART II 
Identification of another Target Lanosterol Synthase in the same pathway. 
 
Retrieval of PDBID of Lanosterol Synthase from PDB ( PDBID 1W6J) 
 
Finding out inhibitors of Lanosterol Synthase 
 
Search for related compounds in PUBCHEM 
 
Prediction of active sites of Lanosterol synthase using CASTP 
 
Docking of these inhibitors with Lanosterol synthase 
 
Choosing the Binding energy values obtained with these as Positive control in this case. 
 
 PART III 
Cross docking of natural molecules used for our 1st target HMGCoA reductase with our 2nd 
target Lanosterol Synthase. 
 
Comparing them with positive control obtained in PART2 
 
Identification of best Binding energies of natural ligands docked with Lanosterol synthase. 
 
Prediction of Toxicity of the inhibitors. 
 
Prediction of Drug likeness of these inhibitors 
 
Molecular visualization of all inhibitors in PYMOL 
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5. MATERIALS AND METHODS 
5.1   MATERIALS: 
5.1.1 REQUIREMENT OF FILES: 
 PDB file of HMGCoA reductase (PDB ID 1DQ9) and Lanosterol synthase (1W6J) 
 Converting .pdb to .pdbqt using MGL tools 
 Geometry optimization using Arguslab  
 mol file of ligand to find the toxicity 
 
5.1.2 REQUIREMENT OF SOFTWARES: 
 Autodock Vina 
 Arguslab 
 MGL tools 
 Ibabel 
 PYMOL 
 
5.1.3 REQUIREMENT OF ONLINE SERVERS: 
 http://www.rcsb.org/ 
 bioserver-3.bioacademy.gr/Bioserver/ChemBioServer/Toxic.php 
 http://www.drugbank.ca/ 
 http://www.uniprot.org/ 
 http://www.ncbi.nlm.nih.gov 
 www.chemicalize.org 
 http://sts.bioengr.uic.edu/castp/ 
 5.2 METHODS: 
In this Insilco based screening, we have selected HMGCoA reductase (PDB ID 1DQ9) and  
Lanosterol Synthase (PDB ID 1W6J) both of which play a critical role in the cholesterol 
biosynthesis in liver 
5.2.1 PREPARATION AND SELECTION OF TARGET MOLECULES OF HMGCOA 
REDUCTASE, LANOSTEROL SYNTHASE: 
 HMGCoA reductase (PDB ID 1DQ9) and Lanosterol synthase (PDB ID 1W6J) was 
downloaded from the protein data bank (http://www.rcsb.org/pdb), which is a complex 
catalytic portion of human HMGCoA reductase with HMGCoA. We obtained PDBIDs 1DQ9, 
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1DQ8, 1DQA for HMGCoA reductase. We obtained 1W6J, 1W6K for Lanosterol synthase. 
Among them we selected 1DQ9 for HMGCoA reductase and 1W6J for Lanosterol synthase as 
they have maximum resolution among others and low polymers and ligands attached to it. We 
then download the required files 
 
5.2.2 SELECTION OF LIGAND MOLECULE FOR HMGCOA REDUCTASE AND 
LANOSTEROL SYNTHASE: 
We searched for different natural treatments which are known to lower cholesterol in our body. 
We studied the ancient method of treatment for heart diseases. We investigated different 
antioxidant foods, natural molecules and listed them. We also found that a class of Quinuclidine 
inhibitors [6] are known to inhibit Lanosterol synthase. We then opened PUBCHEM and 
searched for the structure and files required for different molecules mentioned above. We 
downloaded the required .sdf. We later converted the file into .pdb and .pdbqt. 
 
 
 
 
5.2.3 PREDICTION OF ACTIVE SITE OF PROTEIN: 
Active sites of HMGCoA reductase and Lanosterol synthase were predictes using CASTP. We 
open http://sts-fw.bioengr.uic.edu/castp/calculation.php in our taskbar. We submit the PDBID 
of required protein in the search box. We obtain different amino acid residues present at the 
active site of our required protein. For HMGCoA reductase we found four residues GLU559, 
LYS691, ASP767 and HIS866 as catalytic portions of our active site. We later analyzed the 
Figure 3: Crystallographic structure of 
Lanosterol synthase with PDB ID 1W6J 
Figure 4: Crystallographic structure of 
HMGCoA reductase with PDB ID 1DQ9 
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catalytic aminoacid chains using UNIPROT. We then predicted the binding pockets using 
CASTP. We found HIS232, ASP455 as amino acid residues at active site for Lanosterol 
synthase.  
 
Figure 5: CASTP analysis of Active Sites of HMGCoA Reductase with PDB ID 1DQ9, showing 559 
Amino acid residue of catalytic portion 
5.2.4 DOCKING: 
Docking is a procedural method to predict the preferred orientation of one molecule to another 
when bound forming a stable complex. Docking [11] is important in Drug designing which is 
used to calculating the binding alignment of small molecular drugs or inhibitors to their protein 
targets and can predict affinity and activity of complex formed. Docking is important in rational 
drug designing. Receptor and ligand are important for this docking study. Receptor is a 
receiving molecule mostly a protein. Ligand is its complementary partner which binds to 
receptor forming a complex.  
In this study we have used Arguslab, Mgl tools, Autodock vina dock engine for obtaining our 
results 
5.2.5 SELECTION OF TARGET PROTEIN: 
We used http://www.rcsb.org/pdb/home/home.do to choose the target protein file. We obtained 
PDBIDs 1DQ9, 1DQ8, 1DQA for HMGCoA reductase. We obtained 1W6J, 1W6K for 
Lanosterol synthase. Among them we selected 1DQ9 for HMGCoA reductase and 1W6J for 
Lanosterol synthase as they have maximum resolution among others and low polymers and 
ligands attached to it. We then download the required files. 
Page | 18  
 
5.2.6 VISUALIZATION OF MOLECULE USING PYMOL: 
With the help of PYMOL, we visualize the molecules so that we can obtain better quality 3D 
images of all molecules (small, biological, large etc ).  
 
Figure 6: Example for PYMOL visualization of Biological molecules 
 
5.2.7 TOXICITY PREDICTION USING CHEMBIOSERVER: 
Select the required molecule in .pdb and open it in Ibabel. Convert the .pdb file into .mol in 
Ibabel and save it. Now Chembioserver website was opened. 
o Open " Toxicity filtering " 
o Select the "choose file" and choose the .mol file. 
o Press " Proceed data " button below 
o Download the toxicity results file. 
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Figure 7: Shows the list of Organic Toxic compounds in ChemBioServer Toxicity prediction 
server 
The online server "Chembioserver" recognizes a list of organic toxic compounds. This server 
checks if the molecule contains any of organic toxic compounds. If it does not contain any of 
the organic toxic compounds, the result is PASS i.e Nontoxic. If it contains any toxic 
compounds, the result is FAIL i.e Toxic. 
 
5.2.8 DRUGLIKENESS OF OUR SELECTED INHIBITORS 
Druglikeness is used in drug designing to know how druglike a molecule or substance is 
considering factors like bioavailability. Properties of druglike molecule include solubility, 
molecular weight, molar refractivity, pharmacological properties, ligand efficiency, lipophilic 
efficiency. Partition coefficient. We used http://www.chemicalize.org/ to find out different 
properties for analysis of Druglikeness properties. 
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6 RESULTS 
6.1 PYMOL VIZUALIZATION OF STATINS: 
 
 
 
 
 
 
 
 
 
Figure 9: Visualized Structure of Lovastatin 
(Drug Bank ID DB00227) in PYMOL 
Figure 8: Visualized Structure of Pravastatin 
(Drug Bank ID DB00175) in PYMOL 
 
 
Figure 10: Visualized Structure of NADH 
(Drug Bank ID DB00157) in PYMOL 
Figure 11: Visualized Structure of 
Simvastatin (Drug Bank ID DB00641) in 
PYMOL 
 
Figure 12: Visualized Structure of Atorvavastatin (Drug 
Bank ID DB01076) in PYMOL 
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Figure 13: Visualized Structure of 
Fluvastatin (Drug Bank ID DB01095) in 
PYMOL 
 
Figure 14: Visualized Structure of 
Rosuvastatin (Drug Bank ID DB01098) in 
PYMOL 
 
Figure 15: Visualized Structure of 
Serivastatin (Drug Bank ID DB00439) in 
PYMOL 
Figure 16: Visualized Structure of 
Bezafibrate (Drug Bank ID DB01393) in 
PYMOL 
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6.2 PYMOL VIZUALIZATION OF NATURAL INHIBITORS:  
 
    Figure 17: Visualization of pectin using PYMOL        
                  
 
Figure 19: Visualization of Riboflavin using PYMOL 
 
 
Figure 21: Visualization of Glutathione using PYMOL 
Figure 18: Visualization of beta Carotene 
using PYMOL 
 
Figure 20: Visualization of Pantothenic acid 
using PYMOL 
 
Page | 24  
 
 
     Figure 22: Visualization of Lutein using PYMOL 
 
 
     Figure 24: Visualization of Uric acid using PYMOL 
 
 
Figure 26: Visualization of Ascorbic acid using PYMOL 
 
     Figure 23: Visualization of Naringenin 
using PYMOL 
 
Figure 25: Visualization of Apigenin 
using PYMOL 
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    Figure 27: Visualization of Eugenol using PYMOL 
 
 
  Figure 29: Visualization of Thiamine using PYMOL 
 
 
                                            Figure 31: Visualization of alpha Carotene using PYMOL 
 
Figure 28: Visualization of Hesperetin 
using PYMOL 
 
Figure 30: Visualization of Vitamin E 
using PYMOL 
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6.3 PYMOL VIZUALIZATION OF QUINUCLIDINE INHIBITORS: 
 
Figure 32: Visualization of CID 1006318 using 
PYMOL 
 
 
Figure 34: Visualization of CID 2213595 using 
PYMOL 
 
 
Figure 36: Visualization of CID 2958449 using 
PYMOL 
Figure 33: Visualization of CID 2213568 
using PYMOL 
 
Figure 35: Visualization of CID 2213690 
using PYMOL 
 
Figure 37: Visualization of CID 2958467 
using PYMOL 
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Figure 38: Visualization of CID 3428244 using 
PYMOL 
 
 
Figure 40: Visualization of CID 4398863 using 
PYMOL 
 
 
Figure 42: Visualization of CID 6413427 using 
PYMOL 
 
Figure 39: Visualization of CID 4392376 
using PYMOL 
Figure 41: Visualization of CID 4617056 
using PYMOL 
Figure 43: Visualization of CID 9542937 
using PYMOL 
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Figure 44: Visualization of CID 9542938 using 
PYMOL 
 
 
Figure 46: Visualization of CID 9542940 using 
PYMOL 
 
 
Figure 48: Visualization of CID 11838789 using 
                                     PYMOL 
 
 
Figure 45: Visualization of CID 9542939 
using PYMOL 
 
Figure 47: Visualization of CID 9542941 
using PYMOL 
Figure 49: Visualization of CID 40478367 
using PYMOL 
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6.4 POSITIVE CONTROL 1: 
Table A: Binding energy results obtained on docking HMGCoA reductase with 
available drugs 
Sl 
No 
Name of the 
Compound 
Drug 
Bank ID 
Structure Binding 
Energy 
(K.cal/mol) 
Active 
site 
residue 
1 Lovastatin DB00227 
 
-7.66 559 
catalytic 
portion 
2 Pravastatin DB00175  
 
-6.2 559 
catalytic 
portion 
3 Cerivastatin DB00439  
 
-6.8 559 
catalytic 
portion 
4 Simvastatin DB00641 
 
-7.2 559 
catalytic 
portion 
5 Fluvastatin DB01095 
 
-7.3 559 
catalytic 
portion 
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6 NADH DB00157 
 
-7.8 559 
catalytic 
portion 
7 Bezafibrate DB01393 
 
-6.7 559 
catalytic 
portion 
8 Fluvastatin DB01095 
 
-5.3 691 
catalytic 
portion 
9 Bezafibrate DB01393 
 
-5.6 691 
catalytic 
portion 
10 NADH DB00157 
 
-7.8 767 
catalytic 
portion 
11 Fluvastatin DB01095 
 
-7.1 767 
catalytic 
portion 
12 NADH DB00157 
 
-7.7 866 
catalytic 
portion 
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13 Fluvastatin DB01095 
 
-6.9 866 
catalytic 
portion 
 
Table B: Binding Energy results obtained on Docking HMGCoA reductase 
with natural molecules at 767 Catalytic portion of active site 
Sl No Name of the 
natural 
Compound 
Structure Source Binding 
Energy 
(K.cal/mol) 
1 Apigenin  
 
Vegetables,
fruits, 
spices etc 
-7.2 
2 -carotene  
 
Fruits, 
carrots, 
vegetables 
-6.5 
3 -carotene  
 
Carrots, 
sweet 
potato etc 
-7.1 
4 Ascorbic acid  
 
Citrus 
fruits 
-5.2 
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5  
Epigallo 
catechin 
Gallate 
 
 
Green tea, 
fruits, nuts 
-7.7 
6 Eugenol  
 
Herbs, 
spices 
-5.0 
7 Glutathione  
 
Garlic, 
onions etc 
-5.7 
8 Hesperetin  
 
Citrus 
fruits 
-7.3 
9 Lutein  
 
Plants and 
leafy 
vegetables 
-6.6 
10 Naringenin  
 
Citrus 
fruits 
-7.3 
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11 Pantothenic 
acid 
 
 
Yoghurt, 
eggs, meat 
etc 
-5.6 
12 Pyridoxine  
 
Fish, meat, 
liver etc 
-4.9 
14 Riboflavin  
 
Leafy 
foods, 
mushroom
s, liver, 
milk etc 
-4.9 
15 Thiamine 
 
 
Eggs, liver, 
chicken, 
mutton etc 
-6.4 
16 Tocoferol  
 
Nuts, 
seeds, 
vegetable 
oils etc 
-6.7 
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17 Uric acid 
 
Seafoods, 
meat etc 
-5.6 
18 Vitamin E 
 
Sunflower 
oil, 
almond, 
papaya etc 
-6.8 
 
 
Table C: Binding Energy results obtained on Docking HMGCoA reductase 
with natural molecules at 866 Catalytic portion of active site 
Sl No Name of the 
natural 
Compound 
Structure Source Binding 
Energy 
(K.cal/mol) 
1 Apigenin  
 
Vegetables,
fruits, 
spices etc 
-6.4 
2 -carotene  
 
Fruits, 
carrots, 
vegetables 
-4.0 
3 -carotene  
 
Carrots, 
sweet 
potato etc 
-5.4 
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4 Ascorbic acid  
 
Citrus 
fruits 
-5.1 
5 Epigallo 
catechin 
Gallate 
 
 
Green tea, 
fruits, nuts 
-7.1 
6 Eugenol  
 
Herbs, 
spices 
-4.9 
7 Glutathione  
 
Garlic, 
onions etc 
-5.5 
8 Hesperetin  
 
Citrus 
fruits 
-6.9 
9 Lutein  
 
Plants and 
leafy 
vegetables 
-5.1 
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10 Naringenin  
 
Citrus 
fruits 
-6.6 
11 Pantothenic 
acid 
 
 
Yoghurt, 
eggs, meat 
etc 
-5.2 
12 Pyridoxine  
 
Fish, meat, 
liver etc 
-5.0 
13 Riboflavin  
 
Leafy 
foods, 
mushroom
s, liver, 
milk etc 
-5.0 
14 Thiamine 
 
Eggs, liver, 
chicken, 
mutton etc 
-5.9 
15 Tocoferol  
 
Nuts, 
seeds, 
vegetable 
oils etc 
-5.5 
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16 Uric acid  
 
Seafoods, 
meat etc 
-5.3 
17 Vitamin E 
 
Sunflower 
oil, 
almond, 
papaya etc 
-5.3 
 
Table D: Toxicity and Drug likeness of above natural compounds 
Sl No Name of the natural 
Compound 
Toxicity Result Log P 
Value 
(partition 
co-efficient) 
1 Apigenin Non toxic 2.71 
2 Ascorbic acid Non toxic -1.91 
3 Epigallo catechin 
Gallate 
Non toxic 3.08 
4 Eugenol Non toxic 2.61 
5 Glutathione Non toxic -4.68 
6 Hesperetin Non toxic 2.68 
7 Lutein Non toxic 8.55 
8 Naringenin Non toxic 2.64 
9 Pantothenic acid Non toxic -1.36 
10 Pyridoxine Non toxic -0.95 
11 Riboflavin Non toxic -0.92 
12 Thiamine Non toxic -3.10 
13 Tocoferol Non toxic 10.51 
14 Uric acid Non toxic -1.54 
 
Table E: Log P value of Statins 
Sl No Compound Log P value 
1 Pravastatin 1.65 
2 Lovastatin 3.90 
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3 Ceravastatin 2.67 
4 Simvastatin 4.46 
5 Fluvastatin 3.83 
6 Atorvastatin 5.39 
7 Mevastatin 3.62 
8 Rosuvastatin 1.92 
 
6.5 POSITIVE CONTROL 2: 
Table F: Binding energy results obtained on docking Lanosterol synthase with 
identified class of QUINUCLIDINE INHIBITORS and related structures 
inhibiting Lanosterol synthase. 
Sl 
No 
PUBCHEM 
ID 
Structure Molecular  
Weight 
Binding 
Energy 
(k.cal/mol) 
Active 
site 
catalytic 
portion 
1 CID 
1006318 
 
 
416.47 -6.4 HIS 232 
-8.3 ASP 455 
2 CID 
2213568 
 
 
448.58 -5.7 HIS 232 
-6.1 ASP 455 
3 CID 
2213595 
 
 
436.57 -5.8 HIS 232 
-7.0 ASP 455 
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4 CID 
2213690 
 
 
422.54 -5.6 HIS 232 
-7.1 ASP 455 
5 CID 
2958449 
 
 
448.58 -5.1 HIS 232 
-6.7 ASP 455 
6 CID 
2958467 
 
 
436.57 -6.1 HIS 232 
-6.0 ASP 455 
7 CID 
3428244 
 
 
446.54 -6.8 HIS 232 
-7.6 ASP 455 
8 CID 
4392376 
 
 
440.44 -7.1 HIS 232 
-7.7 ASP 455 
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9 CID 
4398863 
 
 
430.49 -7.5 HIS 232 
-8.4 ASP 455 
10 CID 
4617056 
 
 
456.56 -6.8 HIS 232 
-7.7 ASP 455 
11 CID 
6413427 
 
 
287.38 -7.7 HIS 232 
-6.4 ASP 455 
12 CID 
9542937 
 
 
436.57 -5.8 HIS 232 
-6.2 ASP 455 
13 CID 
9542938 
 
 
422.54 -6.8 HIS 232 
-7.3 ASP 455 
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14 CID 
9542939 
 
 
408.52 -6.2 HIS 232 
-7.4 ASP 455 
15 CID 
9542940 
 
 
448.58 -5.6 HIS 232 
-6.6 ASP 455 
16 CID 
9542941 
 
 
434.55 -5.6 HIS 232 
-7.0 ASP 455 
17 CID 
11838789 
 
 
428.48 -7.1 HIS 232 
-8.4 ASP 455 
18 CID 
40478367 
 
 
436.57 -6.5 HIS 232 
-6.2 ASP 455 
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Table G: Toxicity of above Inhibitors against Lanosterol synthase 
Sl No PUBCHEM ID 
of Molecules 
Toxicity Result Organic Toxic 
Group Found 
1 CID 1006318 Non Toxic ---- 
2 CID 2213568 Toxic Aminothiazole 
Group 
3 CID 2213595 Toxic Aminothiazole 
Group 
4 CID 2213690 Toxic Aminothiazole 
Group 
5 CID 2958449 Toxic Aminothiazole 
Group 
6 CID 2958467 Toxic Aminothiazole 
Group 
7 CID 3428244 Non Toxic ---- 
8 CID 4392376 Non Toxic ---- 
9 CID 4398863 Non Toxic ---- 
10 CID 4617056 Toxic Aminothiazole 
Group 
11 CID 6413427 Non Toxic ---- 
12 CID 9542937 Toxic Aminothiazole 
Group 
13 CID 9542938 Toxic Aminothiazole 
Group 
14 CID 9542939 Toxic Aminothiazole 
Group 
15 CID 9542940 Toxic Aminothiazole 
Group 
16 CID 9542941 Toxic Aminothiazole 
Group 
17 CID 11838789 Non Toxic ---- 
18 CID 40478367 Toxic Aminothiazole 
Group 
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Table H: Drug Likeness (Log P and Molar Refractivity) of inhibitors of 
Lanosterol synthase 
Sl No PUBCHEM ID 
OF 
MOLECULES 
Log P Molar Refractivity 
1 CID 1006318 3.48 118.050 
2 CID 2213568 3.32 119.357 
3 CID 2213595 3.34 114.598 
4 CID 2213690 2.48 110.557 
5 CID 2958449 3.32 119.357 
6 CID 2958467 3.34 114.598 
7 CID 3428244 4.97 129.935 
8 CID 4392376 3.26 115.068 
9 CID 4398863 3.54 122.916 
10 CID 4617056 3.27 131.206 
11 CID 6413427 2.12 85.29 
12 CID 9542937 2.61 115.148 
13 CID 9542938 2.26 110.400 
14 CID 9542939 2.12 105.808 
15 CID 9542940 2.99 119.562 
16 CID 9542941 2.86 114.917 
17 CID 11838789 3.34 124.032 
18 CID 40478367 3.34 114.598 
 
Table I: Cross Docking (Using the natural ligands docked with our previous 
target HMGCoA reductase against Lanosterol synthase) 
Sl No Name of the 
natural 
Compound 
Binding 
Energy 
(K.cal/mol) 
1 Apigenin -8.9 
2 Naringenin -8.7 
3 Epigallo catechin 
Gallate 
-7.5 
4 -carotene -4.9 
5 Ascorbic acid -5.3 
6 Eugenol -6.5 
7 Glutathione -6.3 
8 Hesperetin -6.5 
9 Lutein -4.4 
Page | 44  
 
10 -carotene -4.4 
11 Pantothenic acid -6.2 
12 Pyridoxine -5.7 
14 Riboflavin -5.8 
15 Thiamine -5.2 
16 Tocoferol -5.6 
17 Uric acid -6.3 
 
6.6 CROSS DOCKING RESULTS: (Showing a. Apigenin and b. Naringenin with best 
Binding energy results with Lanosterol synthase) 
a. Apigenin b. Naringenin 
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6.7 DOCKING RESULTS (Showing Quinuclidine inhibitors with PUBCHEM ID’s           
a. CID 4398863 b. CID 1138789 c. CID 1006318 with best binding energy results with 
Lanosterol synthase.) 
a. CID 4398863 b. CID 1138789 
c. CID 1006318 
Page | 46  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.8 DOCKING RESULTS (Showing natural molecules a. Naringenin b. Hesperetin c. Apigenin 
with best binding energy results with HMGCoA reductase) 
a. Naringenin b. Hesperetin 
c. Apigenin 
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6.9 FINAL RESULTS (Two molecules Apigenin and Naringenin have shown best Binding 
Energy results on docking with both HMGCoA reductase and Lanosterol synthase. This shows 
they can inhibit pathway by acting against both targets) 
 
 APIGENIN NARINGENIN 
CHEMICAL 
STRUCTURE 
  
PYMOL 
VISUALIZED 
STRUCTURE 
  
Docking result 
with HMGCoA 
reductase 
 
-7.2 kcal/mol 
 
-7.3 kcal/mol 
Docking result 
with Lanosterol 
synthase 
 
-8.9 kcal/mol 
 
-8.7 kcal/mol 
Toxicity Non toxic Non toxic 
Partition 
coefficient(LogP) 
 
2.71 
 
2.84 
Molecular 
refractivity 
 
72.914 
 
71.290 
Molecular 
formula 
C15H10O5 C15H12O5 
Molecular mass 270.24 g/mol 272.2528 g/mol 
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CHAPTER 7 
DISCUSSION 
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7. DISCUSSION: 
Hyperlipidemia is elevated level of cholesterol in the body. Major production of cholesterol 
takes place in the liver through Mevalonate pathway. Many enzymes HMGCoA synthase, 
HMGCoA reductase, Farnesyl PP synthase, Lanosterol synthase, Squalene synthase play a 
major role in the cholesterol biosynthesis pathway. So in our drug designing study, we have 
selected two important enzymes HMGCoA reductase and Lanosterol synthase as our targets. 
We found that there are already available drugs acting against HMGCoA reductase known as 
Statins. We obtained the active sites of our target using CASTP. After prediction of our active 
sites, we found the binding energies on docking HMGCoA reductase with Statins and results 
obtained was noted as POSITIVE CONTROL 1. There binding energies ranged from about -
6.0 kcal/mol to -8 kcal/mol and this range is choosen as POSITIVE CONTROL 1. We then 
studied for some natural treatment and found some natural molecules which are known to lower 
cholesterol. We obtained the structures of those natural molecules. We docked them with 
HMGCoA reductase and compared the binding energies obtained with the POSITIVE 
CONTROL 1. We found that Apigenin, Naringenin, Hesperitin showed best results with 
binding energy values -7.2 kcal/mol, -7.3 kcal/mol, -7.3 kcal/mol. In the next stage, we targeted 
another enzyme Lanosterol synthase responsible for the same pathway in later stages. We 
searched for known inhibitors available against Lanosterol Synthase and found a class of 
Quinuclidine inhibitors acting against Lanosterol Synthase. We obtained the structures of those 
inhibitors, predicted the active sites of Lanosterol synthase and docked them with Lanosterol 
Synthase. We found the binding energies obtained were chosen as POSITIVE CONTROL 2 in 
this case. The binding energy values obtained are ranging from -8.4 kcal/mol to -6 kcal/mol. 
This is the noted POSITIVE CONTROL 2. Quinuclidine inhibitors CID 1006318, CID 
4398863, CID 1138789 showed best binding energy results with Lanosterol Synthase. Their 
values are found to be -8.3 kcal/mol, -8.4 kcal/mol, -8.4 kcal/mol respectively. Now we have 
cross docked the previous natural ligands used against HMGCoA reductase with Lanosterol 
Synthase. We compared them with the POSlTIVE CONTROL 2 and noted the best results. We 
found that Apigenin and Naringenin showed highest Binding energy values with Lanosterol 
synthase. Their value are found to be -8.9 kcal/mol, -8.7 kcal/mol. We later predicted the 
toxicity and druglikeness of all inhibitors we used for docking. Apigenin and Naringenin are 
found to be non toxic and had Log P value 2.71 and 2.64 respectively.  
Page | 50  
 
  These results show that both Apigenin and Naringenin prevent the pathway by inhibiting at 
both places of the cholesterol biosynthesis pathway. Druglikeness properties show that both 
Apigenin and Naringenin can act like drugs against Hyperlipidemia . 
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CHAPTER 8 
CONCLUSION 
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8. CONCLUSION 
We have targeted two enzymes responsible for the cholesterol biosynthesis pathway in liver. 
They are HMGCoA reductase and Lanosterol synthase. We have searched for already available 
drugs in the market acting against HMGCoA reductase called Statins. In our docking study, we 
have predicted the active sites of HMGCoA reductase. We docked HMGCoA reductase with 
Statins and binding energy values were taken as positive control. We then studied for some 
natural treatment and found some natural molecules which are known to lower cholesterol. We 
obtained the structures of those natural molecules. We docked them with HMGCoA reductase 
and compared the binding energies obtained with the positive control. In the next stage, we 
targeted another enzyme Lanosterol synthase responsible for the same pathway in later stages. 
We searched for known inhibitors available against Lanosterol Synthase and found a class of 
Quinuclidine inhibitors acting against Lanosterol Synthase. We obtained the structures of those 
inhibitors and docked them with Lanosterol Synthase. The binding energies obtained were 
chosen as positive control in this case. Now we cross docked the previous natural ligands used 
against HMGCoA reductase over Lanosterol Synthase. We compared them with the positive 
control and noted the best results. We later predicted the toxicity and druglikeness of all 
inhibitors.  
  We found that natural molecules Apigenin and Naringenin show best binding energy results 
with Lanosterol Synthase. Quinuclidine inhibitors CID 1006318, CID 4398863, CID 1138789 
showed best binding energy results with Lanosterol Synthase. Natural molecules Apigenin, 
Naringenin, Hesperetin showed best results with HMGCoA reductase. 
   We found two natural molecules Apigenin and Naringenin inhibiting the pathway at both 
stages  
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